熱門資訊> 正文
VolitionRx Limited从比利时机构获得200万欧元的非稀释性资金
2026-03-31 20:45
- VolitionRx Limited (NYSE AMERICAN: VNRX) on Tuesday said that it secured €2.0 million in non-dilutive financing from Namur Invest and Wallonie Entreprendre.
- The company said it will use the proceeds to support development of its Nu.Q product portfolio, including regulatory transition work for Nu.Q NETs, as well as ongoing research and development of a lateral flow product aimed at improving access in low-income countries.
- Volition said the funding forms part of its strategy to secure non-dilutive financing to support continued development, adding that total non-dilutive funding to date exceeds $25 million.
- VNRX +0.05% premarket to $0.1901.
- Source: Press Release
More on VolitionRX
- VolitionRx receives NYSE non-compliance notice
- VolitionRx secures $2M financing through amended securities agreement; shares up
- Seeking Alpha’s Quant Rating on VolitionRX
- Historical earnings data for VolitionRX
- Financial information for VolitionRX
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
